Prescription Medicines

Product Monographs:

AVANDIA® Product Monograph

AVANDAMET® Product Monograph

AVANDARYL® Product Monograph

Patient Informed Consent Package:

AVANDIA®, AVANDAMET® and AVANDARYL® Patient Informed Consent Form

AVANDIA® Consumer Information

AVANDAMET® Consumer Information

AVANDARYL® Consumer Information

Health Care Professional Information:

November 9, 2010 - Health Canada Endorsed Information on Important New Restrictions on the use of rosiglitazone (AVANDIA®, AVANDAMET® and AVANDARYL®)

November 1, 2007 - Health Canada endorsed important safety information regarding AVANDIA®, AVANDAMET® and AVANDARYL®

June 1, 2007 - Health Canada endorsed important safety information regarding AVANDIA® and AVANDAMET®

February 23, 2007 - Health Canada endorsed important safety information regarding AVANDIA® and AVANDAMET®

December 19, 2005 - Health Canada endorsed important safety information regarding AVANDIA® and AVANDAMET®

November 13, 2001 - Important safety information regarding AVANDIA®(rosiglitazone maleate)

Public Communications:

November 18, 2010 - Health Canada Endorsed Information on Important New Restrictions on the use of rosiglitazone (AVANDIA®, AVANDAMET® and AVANDARYL®)

November 6, 2007 - Health Canada endorsed important safety information regarding AVANDIA®, AVANDAMET® and AVANDARYL®

May 30, 2007 - Health Canada endorsed important safety information on AVANDIA® and AVANDAMET®

February 28, 2007 - Health Canada endorsed important safety information on AVANDIA® and AVANDAMET®

December 20, 2005 - Health Canada endorsed important safety information on AVANDIA® and AVANDAMET®

November 30, 2001 - Important safety reminder for patients taking oral diabetes drugs of the litazone class, AVANDIA® and Actos®